Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2022Frontiers in ImmunologyOpen Access

Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers

View Full Paper
Ask AI
Bookmark
Share

Authors

SJSeri JeongNLNuri LeeSLSu Kyung Lee

Discussion

Loading...

Member takes

Overview

Prospective longitudinal study demonstrates robust humoral and cellular boosts from BNT162b2 following ChAdOx1 in healthcare workers, indicating effective heterologous vaccination.

Key Points

  • To assess antibody positivity rates, quantitative antibody titer dynamics, and cellular immune responses following a heterologous BNT162b2 booster dose in healthcare workers primed with two doses of ChAdOx1 nCoV-19.
  • Conducted a prospective longitudinal study analyzing 1,027 total samples, evaluating 153 healthcare workers one month after receiving a BNT162b2 booster dose following two primary ChAdOx1 nCoV-19 doses.
  • Assessed humoral responses via Roche total antibody, Abbott IgG, and GenScript neutralizing antibody assays, measured cellular responses using an interferon-γ release assay (IGRA), and recorded self-reported adverse events via questionnaire.
  • All participants (100.0%) were positive across all three antibody assays at one month post-booster, showing significant titer increases over post-dose-two levels: 22.1-fold for Roche total antibody, 14.0-fold for Abbott IgG, and 1.1-fold (97.5% inhibition) for GenScript neutralizing antibody.
  • Cellular immune responses via IGRA were positive in 92.8% of participants, showing weak or negligible correlation with antibody titers, while 72.5% of recipients reported mild adverse reactions.

Cite This Study

Jeong et al. (2022) studied this question.

synapsesocial.com/papers/6a9e8987e42e413fea368102https://doi.org/10.3389/fimmu.2022.859019
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B-092 Humoral Immune Response after Prime and Boost Vaccination against SARS-CoV-2: a Follow-up Study among Healthcare Workers2025
  2. 2Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination2024 · 2 citations
  3. 3Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico2024 · 1 citations
  4. 4Longevity and Magnitude of Antibody Responses After Homologous and Heterologous COVID-19 Booster Vaccinations in Bangladesh2026
  5. 5Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™)2024